BMS links with Apexigen to test cancer immunotherapy combo

by | Apr 13, 2017 | | 0

Bristol-Myers Squibb and Apexigen are to test a combination of Opdivo and the latter’s investigational compound APX005M in patients with advanced solid tumours.

Read More